<div id="readability-page-1"><div>ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc. The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca’s Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers) infringes a Revolution patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca’s shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026. What Should I Do? At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. [LEARN MORE ABOUT SECURITIES CLASS ACTIONS] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTk5Mjg3ODFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTk5Mjg3ODFyMQ"/> Kirby McInerney LLP Lauren Molinaro, Esq. 212-699-1171 https://www.kmllp.com https://securitiesleadplaintiff.com/ investigations@kmllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260519928781/en/</div></div>

ERAS

RVMD

动态生物技术与基因组 ETF - Invesco

Kirby McInerney LLP 正在调查针对 Erasca, Inc.（纳斯达克代码：ERAS）的潜在索赔，涉及在 Revolution Medicines 提出的专利侵权指控后可能违反联邦证券法的情况。这一消息导致 Erasca 的股票下跌了约 48%。目前尚未提起诉讼，调查仍在进行中。拥有信息或感兴趣的投资者被鼓励与该律师事务所联系

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

MorningStar

Erasca

Revolution Medicines

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS 投资者警报：Kirby McInerney LLP 正在调查涉及 Erasca, Inc.的潜在索赔